Biotechnology

HENLIUS

Organon Canada and Henlius Launch Denosumab Biosimilars

Fosun Pharma Subsidiary Passes GMP Compliance Inspection for Pertuzumab Injection

Firmus Hanlin's HLX3902 Injection Approved for Phase I Clinical Trials

Hengrui Medicine's HLX01 Subsidiary Starts Phase II Trial in Australia for HLX43 Combination Therapy

Hengrui Medicine HLX04-O wAMD Phase 3 Trial Meets Primary Endpoint, Comparable to Lucentis

Bei Hong Hanlin Allocates and Issues 1.7068 Million New Shares to Trustee

Hengrui Medicine's Hansun approved by NMPA for new gastric cancer indications

Firmus Hanlin's Srulimab Injection Approved for New Gastric Cancer Indication

Hengrui Confirms First Patients Treated in Global Phase III of HLX22

Hengrui Medicine's HLX17 Completes First Patient Dosing in US Phase 1 Study, Clinical Trials Proceeding in China

CICC Maintains Outperform Rating and HKD 102.91 Target Price for Henlius Biotech

Hanlim's Gastric Cancer Drug H Shows Positive Phase III Results, Potentially Eliminating Need for Post-op Chemo, as Domestic Innovation Drugs Accelerate Globalization

Immunogen's Hanbeiyou Approved by NMPA for Launch, Expanding Breast Cancer Treatment Portfolio

Henlius: First Patient Dosed in International Phase 2/3 Study of HLX43 Alone or Combined with HLX07 for NSCLC Treatment

Shanghai Henlius Biotech Initiates Phase 2/3 Clinical Trial of HLX07 Combination Therapy for Lung Cancer

Hengrui HLX15-SC New Drug Clinical Progress, First Patient Dosed

Henlius's Srulimab Receives Positive CHMP Opinion for Approval in EU

Hengrui Medicine HLX316 completes first patient dosing in phase 1 trial for solid tumors

Alligator Bioscience states HLX22 follow-up studies support continued development

Hengrui Medicine's HLX43 Completes First Patient Dosing in EU for NSCLC Phase 2 Trial

SINOFORTUNE FIN

PAN ASIA DATA H

HUASHENG INTL

IMAGI INT'L

SUPERLAND GROUP

QIANHAI HEALTH

STELUX HOLDINGS

JOLIMARK

CASSAVA RES

I-CABLE COMM

02696

Organon Canada and Henlius have launched BILDYOS® and TUZEMTY®, biosimilars to PROLIA and XGEVA, in Canada. This expansion adds two products to Organon's Canadian biosimilar portfolio, aiming to broaden access to bone-care treatments for osteoporosis and cancer-related bone events while reducing healthcare costs.

StockTitan

Organon

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA | OGN Stock News

Shanghai Henlius Biologics passed a China GMP inspection for its HANBEIYOU (pertuzumab injection) production lines. The inspection covered drug substance, product, and packaging lines at the Songjiang First Plant in Shanghai. This result confirms the company's eligibility for commercial production of HANBEIYOU in mainland China under current GMP requirements.

PUBT

Henlius unit Shanghai Henlius Biologics passes China GMP inspection for HANBEIYOU production lines

Citic Securities analyst maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H on June 9 and set a price target of HK$119.00.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Currently, the analyst consensus on Shanghai Henlius Biotech, Inc. Class H is a Strong Buy with an average price target of HK$99.12.

Tip Ranks

CITIC SEC

CITIC Securities Co., Ltd.

Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citic Securities

Alligator Bioscience commented on Henlius' update regarding the global Phase 3 trial of HLX22. Henlius confirmed that the first patients have been dosed across all participating regions, including China, Japan, Korea, Latin America, Australia, the US, and Europe. This milestone signals continued progress in the study for the anti-HER2 monoclonal antibody. Alligator is entitled to 35% of revenue from AbClon's sublicense to Henlius, representing a potential long-term revenue opportunity.

MorningStar

Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22

02442

01672

02039

01530

02648

02723

09926

02616

06990

EASY SMART GP(02442) fell 15.56%, with a trading turnover 72.4 Million HKD, and a year-to-date rose 134.3%. ASCLETIS-B(01672) fell 12.46%, with a trading turnover 109.0 Million HKD, and a year-to-date fell 9.3%. CIMC(02039) fell 8.94%, with a trading turnover 254.6 Million HKD, and a year-to-date rose 0.2%.

Top Gainers&Losers

EASY SMART GP

ASCLETIS-B

CIMC

3SBIO

Anjoy Food

DEEPZERO

AKESO

CSTONE PHARMA-B

SKB BIO

Top 10 HK Stock Losers (6.2)

Shanghai Henlius Biotech, Inc. has received Australian approval for a phase 1 clinical trial of HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced solid tumors. This therapy aims to combine targeted drug delivery with immune mechanisms to inhibit tumor growth. If successful, it would be the first bispecific ADC against both targets. The company warns of the risks in development and commercialization. Analysts rate the stock as a Buy with a price target of HK$99.78, and the current market cap is HK$39.13B.

Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial

516500

159849

520880

159992

510660

588250

159316

512290

Shanghai Henlius Biotech, Inc. has received EU approval for two new uses of its anti-PD-1 antibody serplulimab (HETRONIFLY) for treating esophageal squamous cell carcinoma and non-squamous non-small cell lung cancer. This approval, supported by phase 3 data, enhances Henlius's oncology portfolio and commercial prospects in Europe and India through its partnership with Intas Pharmaceuticals. The stock is rated a Buy with a target price of HK$99.78.

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

Henlius Wins EU Approval for Two New Serplulimab Cancer Uses

Shanghai Henlius Biotech, Inc. has received FDA approval to conduct a phase 1 clinical trial for HLX05-N, a biosimilar to cetuximab, aimed at treating metastatic colorectal cancer. This follows prior approval from China's National Medical Products Administration. The company anticipates entering a lucrative oncology biosimilar market, with global sales projected at USD 1.66 billion by 2025. Analysts rate the stock as a Buy with a target price of HK$99.78, although successful development is not guaranteed.

First Trust NYSE Arca Biotech Index Fd

Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N

HENLIUS(02696.HK)